Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 14/20 | 0.81 |
| ▸ | WDR77 | Q9BQA1 | 14/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833540 | 0.89 | PRMT5 (1.00) | PRMT5WDR77SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15943979 | 0.82 | PRMT5 (0.82) | PRMT5WDR77SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15833547 | 0.80 | PRMT5 (1.00) | PRMT5WDR77SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22354535 | 0.79 | PRMT5 (0.80) | PRMT5WDR77SMN1; SMN2 | |
| SCHEMBL15833542 | 0.78 | PRMT5 (1.00) | PRMT5WDR77SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15833707 | 0.77 | PRMT5 (1.00) | PRMT5WDR77SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15833646 | 0.76 | KMT2A (0.74) | PRMT5WDR77MEN1KMT2A | |
| SCHEMBL15833708 | 0.76 | MEN1 (0.77) | PRMT5WDR77MEN1KMT2A | |
| SCHEMBL15833539 | 0.76 | PRMT5 (1.00) | PRMT5WDR77SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18776486 | 0.75 | PRMT5 (1.00) | PRMT5WDR77SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777008-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20140228343-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228343-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885SMN1; SMN2 952/4885 |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885SMN1; SMN2 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.